Skip to main content

Advertisement

SpringerLink
Log in

The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with recognised variability in molecular aetiology and clinical outcome. Though the use of agents such as rituximab significantly improves outcome, intrinsic genetic and morphological factors greatly affect the response to treatment. The objective of this study was to evaluate the prognostic value of immunohistochemical subtyping and the International Prognostic Index (IPI) for predicting treatment outcome in Chinese DLBCL patients. We followed 108 cases of DLBCL and performed prognostic analyses based on molecular subtyping of the disease through immunostaining of tissue samples. The use of rituximab conferred a clinical benefit to DLBCL patients regardless of disease subtype. Importantly, this treatment regimen also improved outcomes in patients with the non-germinal centre B-cell-like (GCB) DLBCL subtype, frequently associated with poorer prognosis. Our results suggest that IPI was the best tool for the prediction of treatment outcome in our patient cohort, regardless of treatment regimen. Furthermore, the use of rituximab alongside classical chemotherapy regimens can improve the outcomes for DLBCL patients who exhibit both GCB and non-GCB subtypes of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jaffe ES, Harris NL, Stein H et al (2001) World Health Organization classification of tumors: pathology and genetics of tumors of hematopoetic and lymphoid tissues. IARC Press, Lyon, France

    Google Scholar 

  2. Li JM, Wang L, Shen Y et al (2007) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol 86:639–645

    Article  CAS  PubMed  Google Scholar 

  3. Abramson JS, Shipp MA (2005) Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106:1164–1174

    Article  CAS  PubMed  Google Scholar 

  4. Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    Article  CAS  PubMed  Google Scholar 

  5. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  CAS  PubMed  Google Scholar 

  6. Feugier P, Van HA, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:4117–4126

    Article  CAS  PubMed  Google Scholar 

  7. Habermann TM, Weller EA, Morrison VA et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127

    Article  CAS  PubMed  Google Scholar 

  8. Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391

    Article  CAS  PubMed  Google Scholar 

  9. Sehn LH, Donaldson J, Chhanabhai M et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027–5033

    Article  CAS  PubMed  Google Scholar 

  10. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994

    Article  Google Scholar 

  11. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511

    Article  CAS  PubMed  Google Scholar 

  12. Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 20(346):1937–1947

    Article  Google Scholar 

  13. Shipp MA, Ross KN, Tamayo P et al (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68–74

    Article  CAS  PubMed  Google Scholar 

  14. Wright G, Tan B, Rosenwald A et al (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 19(100):9991–9996

    Article  Google Scholar 

  15. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282

    Article  CAS  PubMed  Google Scholar 

  16. Flieger D, Renoth S, Beier I et al (2000) Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 204:55–63

    Article  CAS  PubMed  Google Scholar 

  17. Ghetie MA, Bright H, Vitetta ES (2001) Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97:1392–1398

    Article  CAS  PubMed  Google Scholar 

  18. Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

    CAS  PubMed  Google Scholar 

  19. Liu YH, Xu FP, Zhuang HG et al (2008) Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol 39:875–884

    Article  CAS  PubMed  Google Scholar 

  20. Oh YH, Park CK (2006) Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci 21:397–405

    Article  CAS  PubMed  Google Scholar 

  21. Shiozawa E, Yamochi-Onizuka T, Takimoto M et al (2007) The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 31:1579–1583

    Article  CAS  PubMed  Google Scholar 

  22. Fu K, Weisenburger DD, Choi WW et al (2008) Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 26:4587–4594

    Article  CAS  PubMed  Google Scholar 

  23. Lenz G, Wright G, Dave SS et al (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313–2323

    Article  CAS  PubMed  Google Scholar 

  24. Nyman H, Adde M, Karjalainen-Lindsberg ML et al (2007) Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109:4930–4935

    Article  CAS  PubMed  Google Scholar 

  25. Saito B, Shiozawa E, Usui T et al (2007) Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. Leukemia 21:2563–2566

    Article  CAS  PubMed  Google Scholar 

  26. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244

    CAS  PubMed  Google Scholar 

  27. Linderoth J, Ehinger M, Akerman M et al (2007) Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. Eur J Haematol 79:146–149

    Article  PubMed  Google Scholar 

  28. Berglund M, Thunberg U, Amini RM et al (2005) Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 18:1113–1120

    Article  CAS  PubMed  Google Scholar 

  29. Chang CC, McClintock S, Cleveland RP et al (2004) Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28:464–470

    Article  PubMed  Google Scholar 

  30. van Imhoff GW, Boerma EJ, van der HB et al (2006) Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 24:4135–4142

    Article  PubMed  Google Scholar 

  31. Liu YY, Leboeuf C, Shi JY et al (2007) Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood 110:339–344

    Article  CAS  PubMed  Google Scholar 

  32. Mounier N, Briere J, Gisselbrecht C et al (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2–associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279–4284

    Article  CAS  PubMed  Google Scholar 

  33. Natkunam Y, Farinha P, Hsi ED et al (2008) LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 20(26):447–454

    Article  Google Scholar 

  34. Farinha P, Sehn L, Skinnider B et al (2006) Strong p53 expression is an independent predictor of outcome in de novo diffuse large B cell lymphoma (DLBCL) treated with either CHOP or CHOP-R. ASH Annual Meeting Abstracts 108, Abstract 812

Download references

Acknowledgements

The authors gratefully acknowledge all members of the Shanghai Institute of Hematology for their support and Professor Xin-Xu Du for pathological review. This work was supported in part by the Shanghai Commission of Science and Technology (Grants 44107025 and 05DZ19317), the National Natural Science Foundation of China (Grants 30570777 and 30750335), the Chinese National High Tech Program (Grant 863:2006AA02A301), the Shanghai Commission of Science and Technology (Grant 08410708800), the Program for New Century Excellent Talents in University, and the Fok Ying Tung Education Foundation (Grant 111035). J-ML, Z-GX, W-LZ, and Z-XS contributed to the concept and experimental design of this work. Z-GX and Z-ZX performed the research. S-QZ, FD, YC, Q-SC, YZ, QZ, and J-PH collected the data; interpretation and analysis of the data was performed by Z-GX and J-ML. Z-GX, W-LZ, and J-ML wrote the paper. All authors read and approved the final manuscript.

Conflict of interest

The authors declare that they have no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Zu-Guang Xia, Zi-Zhen Xu, Wei-Li Zhao, Shu-Qing Zhao, Fei Ding, Yu Chen, Qiu-Sheng Chen, Yu Zheng, Qi Zhu, Jun-Pei Hu, Zhi-Xiang Shen & Jun-Min Li

  2. Department of Hematology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China

    Zi-Zhen Xu, Wei-Li Zhao, Shu-Qing Zhao, Fei Ding, Yu Chen, Qiu-Sheng Chen, Yu Zheng, Zhi-Xiang Shen & Jun-Min Li

  3. Department of Hematology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Zu-Guang Xia, Qi Zhu & Jun-Pei Hu

Authors
  1. Zu-Guang Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zi-Zhen Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei-Li Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shu-Qing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fei Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qiu-Sheng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yu Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Qi Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jun-Pei Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Zhi-Xiang Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jun-Min Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun-Min Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xia, ZG., Xu, ZZ., Zhao, WL. et al. The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Ann Hematol 89, 171–177 (2010). https://doi.org/10.1007/s00277-009-0799-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-009-0799-2

Keywords

Search

Navigation